Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

H. Guo

ResearcherPublications, citations & collaboration network

H. Guo is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 6 works, 0 citations, an h-index of 0 and an i10-index of 0.

6
Works
0
Citations
0
h-index
0
i10-index

How has H. Guo's publication output changed over time?

ScholarIQpublication output · 2025
6
2025

What are the most-cited papers on H. Guo?

ScholarIQmost cited works
498P Efficacy and safety of triptorelin pamoate 22.5 mg 6-month formulation in Chinese patients with locally advanced or metastatic prostate cancer: A multicentre, single-arm phase IIIb study
S. Jiang, H. Su, H. Guo, M. Liu, Y. Li, G. Shi, J. Bi, Z. Chen, M. Chen, W. He, Z. Yan, J. Zhang, B. Xue, J-Y Zou, X. Shi, D. Ye
Annals of Oncology. 20250 Citations
489MO A multicenter, single-arm, phase II trial of androgen deprivation therapy in combination with apalutamide in patients with high risk of recurrence after radical prostatectomy (ARES study)
Q. Zhang, L. Xu, X. Qiu, J. Zhuang, S. Zhang, C. Zhou, L. Xu, Haibo Xu, X. Wang, W. Liu, Xiaoyu Jia, H. Guo
Annals of Oncology. 20250 Citations

Related on ScholarIQ

Nanjing Drum Tower Hospital
Institution
490MO Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) in Chinese patients with breast cancer susceptibility gene (BRCA) altered metastatic castration-sensitive prostate cancer (mCSPC): Subgroup analysis of the phase III AMPLITUDE trial
Paper
573P Anatomical adaptability guides approach selection in robotic partial nephrectomy: Equivalent trifecta outcomes with route-specific predictive models
Paper
574P SHOX2-Mediated lymphatic metastasis in pT1 non-clear cell renal carcinoma: Biomarker-driven risk stratification and combined-modality management
Paper
498P Efficacy and safety of triptorelin pamoate 22.5 mg 6-month formulation in Chinese patients with locally advanced or metastatic prostate cancer: A multicentre, single-arm phase IIIb study
Paper
489MO A multicenter, single-arm, phase II trial of androgen deprivation therapy in combination with apalutamide in patients with high risk of recurrence after radical prostatectomy (ARES study)
Paper
470M+ articles · free account